OncoMed Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference

By GlobeNewswire,  June 19, 2014, 08:30:00 AM EDT


REDWOOD CITY, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Sunil Patel, Chief Financial Officer, Senior Vice President, Corporate Development and Finance of OncoMed, will present an overview of the company at the 9th Annual JMP Securities Healthcare Conference being held in New York City.

Mr. Patel will speak on Wednesday, June 25, 2014 beginning at 3:30 pm EDT. To access the live webcast and subsequent archived recording for the presentation, please visit the Investors tab on the OncoMed website at www.oncomed.com.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch 2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-Fzd7, OMP-18R5), and Fzd8-Fc (OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, anti-DLL4/anti-VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10), with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Additional information can be found at the company's website: www.oncomed.com.

CONTACT: Investor Contact:
         OncoMed Pharmaceuticals
         Shari Annes
         Investor Relations
         (650) 888-0902
         shari.annes@oncomed.com

         Media Inquiries:
         BCC PartnersMichelle Corral or
         Karen L. Bergman
         (415) 794-8662 or (650) 575-1509
         mcorral@bccpartners.com or
         kbergman@bccpartners.com

Source: OncoMed Pharmaceuticals, Inc.

This article appears in: News Headlines

Referenced Stocks: OMED


Latest News Video

S&P 500 Movers: PKI, EXPE
S&P 500 Movers: PKI, EXPE           




Most Active by Volume

Company Last Sale Change Net / %
BAC $ 14.91 0.34 ▼ 2.23%
QQQ $ 94.29 0.73 ▼ 0.77%
SIRI $ 3.32 0.06 ▼ 1.78%
MBLY $ 38 unch
AAPL $ 95.71 0.11 ▲ 0.12%
FB $ 72.02 0.63 ▼ 0.87%
AMD $ 3.95 0.04 ▲ 1.02%
TVIX $ 3.8601 0.39 ▲ 11.24%

As of 8/1/2014, 12:42 PM